ArticleChest2010
Early anticoagulation is associated with reduced mortality for acute pulmonary embolism.
Article in Chest, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
101 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Guideline
- Prospective study of the frequency and outcomes of patients with suspected pulmonary embolism administered heparin prior to confirmatory imaging.Thrombosis research · 2012Trial
- Review
- Temporal Trends and Future Projections of P ulmonary Embolism and Top Contributing Causes of death in the United States, 1968-2040: insights from the CDC WONDER database.Journal of thrombosis and thrombolysis · 2026Article
- Initial management of intermediate- and high-risk pulmonary embolism.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2026Review
- Impact of time in therapeutic range (TTR) within the first 72 h on prognosis in patients with pulmonary embolism treated with unfractionated heparin.Journal of thrombosis and thrombolysis · 2026Article
- Article
- The Thromboembolism Heparinization and AntithrombiN Observational Study (THANOS-1).Research and practice in thrombosis and haemostasis · 2026Article
- Venous Thromboembolism in Inherited Platelet Disorders: A Clinical Challenge.Diagnostics (Basel, Switzerland) · 2025Review
- Article
- L-Shaped Association of 24-Hour Urine Output with 3-Month and 1-Year All-Cause Mortality in Patients with Acute Pulmonary Embolism: A Retrospective Cohort Study.Journal of atherosclerosis and thrombosis · 2025Article
- Pulmonary Embolism in Acute Ischaemic Stroke: Evolving Evidence, Diagnostic Challenges, and a Novel Thromboinflammatory Axis Hypothesis.International journal of molecular sciences · 2025Review
- Article
- Hemodynamic improvement with Impella RP in acute massive pulmonary embolism: a narrative review of cardiovascular outcomes and pulmonary catheter pressure assessment.Annals of medicine and surgery (2012) · 2025Review
- Quantitative assessment and risk stratification of random acute pulmonary embolism cases using a deep learning model based on computed tomography pulmonary angiography images.Quantitative imaging in medicine and surgery · 2025Article
- Research progress of artificial intelligence and machine learning in pulmonary embolism.Frontiers in medicine · 2025Review
- A Comprehensive Clinical Acumen Enhanced by Point-of-Care Ultrasonography in Managing Acute Life-Threatening Massive Pulmonary Thromboembolism in a Peripheral Setting: A Case Report.Annals of cardiac anaesthesia · 2025Article
- Efficacy and safety of tranexamic acid combined with low molecular weight heparin versus fondaparinux sodium following total knee arthroplasty: a retrospective cohort study.Frontiers in pharmacology · 2025Article
- Independent Evaluation of a Commercial AI Software for Incidental Findings of Pulmonary Embolism (IPE) on a Large Hospital Retrospective Dataset.Radiology research and practice · 2025Article
- Strategies in Management of Pulmonary Embolism With Acute Ischemic Stroke: A Systematic Review.Journal of clinical medicine research · 2025Review
41 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundAcute pulmonary embolism (PE) may be rapidly fatal if not diagnosed and treated. IV heparin reduces mortality and recurrence of PE, but the relationship between survival and timing of anticoagulation has not been extensively studied.
methodsWe studied 400 consecutive patients in the ED diagnosed with acute PE by CT scan angiography and treated in the hospital with IV unfractionated heparin from 2002 to 2005. Patients received heparin either in the ED or after admission. Time from ED arrival to therapeutic activated partial thromboplastin time (aPTT) was calculated. Outcomes included in-hospital and 30-day mortality, hospital and ICU lengths of stay, hemorrhagic events on heparin, and recurrent venous thromboembolism within 90 days.
resultsIn-hospital and 30-day mortality rates were 3.0% and 7.7%, respectively. Patients who received heparin in the ED had lower in-hospital (1.4% vs 6.7%; P = .009) and 30-day (4.4% vs 15.3%; P < .001) mortality rates as compared with patients given heparin after admission. Patients who achieved a therapeutic aPTT within 24 h had lower in-hospital (1.5% vs 5.6%; P = .093) and 30-day (5.6% vs 14.8%; P = .037) mortality rates as compared with patients who achieved a therapeutic aPTT after 24 h. In multiple logistic regression models, receiving heparin in the ED remained predictive of reduced mortality, and ICU admission remained predictive of increased mortality.
conclusionsWe report an association between early anticoagulation and reduced mortality for patients with acute PE. We advocate further study with regard to comorbidities to assess the usefulness of modifications to hospital protocols.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.